Innovation Trends in AD Research –the shift to increasingly individualised trial design, therapeutics and care. Alzheimer’s disease (AD) research is entering a new phase of innovation, highlighted by a number of advances presented at recent conferences such as CTAD 2024 in Madrid and AD/PD 2025 in Vienna.
Imaging: Advancing Biomarker Research for Alzheimer's Disease Diagnosis In an article published in the latest edition of the Journal for Clinical Studies, IXICO’s Chief Scientific Officer Robin Wolz outlines how data from the landmark Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation (GAP) and supported by IXICO as imaging partner, can help better understand the…
This week we will be at the ADPD 2025 International Conference talking about some of our latest biomarker research. Specifically, we are presenting an AI-based approach to differentiate different types of dementia from magnetic resonance imaging (MRI).
Alzheimer's disease is a complex neurodegenerative disorder that affects millions of people worldwide. While there is no cure for the disease, ongoing research efforts have led to significant advancements in our understanding of the underlying mechanisms that drive the disease.